# OnCo record biocad (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/biocad/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "biocad" ;
  schema:name "Biocad"@en ;
  schema:alternateName "BIOCAD"@en ;
  schema:description "Biocad is a Russian biotechnology company that makes biosimilars of rituximab, bevacizumab and trastuzumab and developed prolgolimab, the first anti-PD-1 antibody approved in Russia, now tested with its anti-CTLA-4 partner nurulimab in melanoma."@en ;
  schema:url <https://onco.cc/companies/biocad/>, <https://biocad.ru/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://biocad.ru/>, <https://clinicaltrials.gov/search?lead=Biocad> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "RU" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/bcd-100/>, <https://onco.cc/drugs/bcd-217/> ;
  onco:institutions <https://onco.cc/institutions/blokhin-cancer-center/>, <https://onco.cc/institutions/petrov-institute/> ;
  onco:trials <https://onco.cc/trials/nct05732805/>, <https://onco.cc/trials/nct05751928/>, <https://onco.cc/trials/nct06640530/>, <https://onco.cc/trials/nct05802225/>, <https://onco.cc/trials/nct07108309/>, <https://onco.cc/trials/nct06668792/>, <https://onco.cc/trials/nct07742215/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/>, <https://onco.cc/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/> .